|[December 11, 2013]
AGTC Scientific Founders William W. Hauswirth and R. Jude Samulski Receive Pioneer Awards for Seminal Work in Gene and Cell Therapy
GAINESVILLE, Fla. --(Business Wire)--
Genetic Technologies Corporation, a clinical stage biotechnology
company developing adeno-associated virus (AAV)-based systems to deliver
human therapeutics, today announced that two of the company's scientific
founders, William W. Hauswirth, Ph.D., University of Florida College of
Medicine, and R. Jude Samulski, Ph.D., Gene Therapy Center, University
of North Carolina at Chapel Hill, have been named Pioneer Award winners
for their seminal work in gene and cell therapy by the peer-reviewed
journal Human Gene Therapy. Dr. Hauswirth, nominated for his work
in gene therapy for eye disorders, and Dr. Samulski, nominated for
contributions to basic AAV vector technology, were selected by a blue
ribbon panel commissioned by Human Gene Therapy to identify 12
scientists who have made influential contributions to cell and gene
therapy research over an extended period of time.
"On behalf of AGTC I'd like to congratulate Dr. Hauswirth and Dr.
Samulski on receiving this prestigious and well-deserved reconition,"
said Sue Washer, President and CEO of AGTC. "With their groundbreaking
research over the years, both men have been instrumental in the
advancement of not only AGTC, but the field of gene therapy as a whole."
Dr. Hauswirth, a member of AGTC's Ophthalmology Scientific Advisory
Board, and Dr. Samulski founded AGTC in 1999 along with three other
scientific leaders: Barry Byrne, M.D., Ph.D., Director, UF Powell Gene
Therapy Center, Professor, Pediatrics and Molecular Genetics &
Microbiology, Associate Chair, Pediatrics University of Florida; Dr.
Terence Flotte, M.D., dean of the School of Medicine and provost &
executive deputy chancellor of The University of Massachusetts Medical
School; and Nicholas Muzyczka, Ph.D., Professor, Department of Molecular
Genetics and Microbiology, College of Medicine, University of Florida.
Gene therapy replaces broken genes with normal functional genes,
allowing a patient's own body to produce proteins to treat their
illness. AGTC is focused on the clinical development of novel
therapeutics for patients with unmet medical needs utilizing its safe
and effective delivery system, the adeno-associated virus (AAV). AAV
delivers healthy copies of the gene, replacing defective copies. The
technology offers possible solutions to problems associated with a wide
spectrum of illnesses including Alpha-1 Antitrypsin Deficiency,
Age-Related Macular Degeneration, Pompe's Disease, and Leber's
Congenital Amaurosis (LCA).
AGTC is a privately held, clinical-stage biotechnology company creating
first-in-class treatments for rare eye and lung diseases caused by
mutated genes. The company currently has five programs in development
from pre-clinical through Phase 2. A leader in gene therapy treatments,
AGTC uses a safe and effective delivery system, the adeno-associated
virus (AAV). A single injection provides long-lasting treatment, leading
to a better quality of life for patients worldwide. AGTC is
headquartered in Alachua, FL. For more information, please visit www.agtc.com.
[ InfoTech Spotlight's Homepage ]